SITC 2023

Tempus is advancing precision medicine through the practical application of artificial intelligence in healthcare. We are pleased to share our latest scientific and clinical research findings along with new AI-enabled technology during SITC’s 38th Annual Meeting.

Schedule a meeting with us

Poster Presentations

Poster Presentations

November 3, 2023

Time
9:00am – 7:00pm PDT

Location
Exhibit Hall B
Presentation Number
163

A multi-modal, pan-cancer atlas of tumor-immune states across primary and metastatic disease using a large, real-world database

Authors
Prerna Jain (Tempus), Michelle M. Stein (Tempus), Paul Fields (Tempus), Bolesław Osinski (Tempus), Luca Lonini (Tempus), Ariane Lozac’hmeur (Tempus), Rohan Joshi (Tempus), Halla Nimeiri (Tempus), Martin C. Stumpe (Tempus), Kate Sasser (Tempus), Catherine Igartua (Tempus), Justin Guinney (Tempus), Mary Nora Disis (School of Medicine, University of Washington)

Analysis was conducted using Tempus IO, an immunogenomics platform encompassing molecular data and immunophenotyping algorithms built upon DNA-seq, RNA-seq, imaging, and clinical data from a large, real-world patient database. In this expansive analysis of immuno-oncology (IO) characteristics from multimodal data, significant differences in tumor-immune states were observed between primary and metastatic sites, and indications, with important implications for immuno-oncology (IO) treatment strategies. These data provide valuable and timely insights for IO research, where simultaneous assessment of molecular and clinical traits is required.

Time
9:00am – 7:00pm PDT

Location
Exhibit Hall B
Presentation Number
181

Associations between multimodal immune biomarkers and clinical outcomes in a real-world non-small cell lung cancer cohort

Authors
Michelle M. Stein, PhD (Tempus), Mario Rosasco, PhD (Tempus), Denise Lau, PhD (Tempus), Yinjie Gao, MS (Tempus), Rotem Ben-Shachar, PhD, (Tempus) Justin Guinney, PhD (Tempus) Halla Nimeiri, MD, (Tempus) Nisha Mohindra, MD (Northwestern University)

A comparative study assessing the association between previously described biomarkers of immune checkpoint inhibitor (ICI) response and outcomes in a real-world mNSCLC cohort was performed. In this study, we demonstrated that RNA-based immune signatures are significantly associated with clinical benefit and may supplement well-established ICI biomarkers in therapy selection. These RNA-based immune signatures need to be prospectively validated in future studies.

November 4, 2023

Time
9:00am – 8:30pm PDT

Location
Exhibit Hall B
Presentation Number
34

Association of a novel circulating tumor fraction DNA biomarker of treatment response monitoring and clinical outcomes in a real-world, diverse pan-cancer cohort treated with immunotherapy

Authors
John Guittar (Tempus Labs, Inc), Gentzler, Ryan (University of Virginia), Akash Mitra (Tempus Labs, Inc), Michelle M. Stein (Tempus Labs, Inc), Christine Lo (Tempus Labs, Inc), Wei Zhu (Tempus Labs, Inc), Terri Driessen (Tempus Labs, Inc), Justin Guinney (Tempus Labs, Inc), Halla Nimeiri (Tempus Labs, Inc), Rotem Ben-Shachar (Tempus Labs, Inc), Jyoti Patel (Feinberg School of Medicine, Northwestern University)

This poster presents xF Monitor – a new circulating tumor DNA (ctDNA) assay which detects and monitors changes in circulating tumor fraction to determine early response to immunotherapy for patients with advanced cancers. Tempus’ xF Monitor assay measures quantitative molecular changes in ctDNA tumor fraction by utilizing diverse genomic events, dynamically weighting somatic variant allele frequencies and copy number variants, while using germline information to inform these estimates. The algorithm that powers xF Monitor – xF ctDNA tumor fraction – utilizes multiple single input models and weights their importance based on failure modes observed in Tempus’ multimodal database.

Time
9:00am – 8:30pm PDT

Location
Exhibit Hall B
Presentation Number
158

Interrogating real world tumor-infiltrating T-cell repertoires to identify antigen enriched TCRs in a large pan-cancer clinical cohort

Authors
Paul A. Fields (Tempus), Fu Luo (Tempus), Taylor S Harding (Tempus), Michelle M Stein (Tempus), Catherine Igartua (Tempus), Justin Guinney (Tempus)

In this study, we analyzed a large, real-world, clinicogenomic database to identify public T-cell receptor (TCR) repertoires associated with HLA-specific neoantigens and viral epitopes. The database includes over 130k patients with TCR data covering a diverse landscape of HLA genotypes and tumor neoantigens. By incorporating routine TCR repertoire profiling into a high-volume clinical genomic sequencing program, we have developed a rich, multi-modal resource for studying complex tumor-immune interactions. This dataset is a valuable resource for TCR therapeutic discovery, and can help identify naturally occurring TCRs that may minimize on-target, off-tumor toxicity.

Time
9:00am – 8:30pm PDT

Location
Exhibit Hall B
Presentation Number
620

Multimodal Real World Data reveals immunogenomic drivers of acquired and primary resistance to immune checkpoint blockade

Authors
Mohamed Reda Keddar (AstraZeneca), Sebastian Carrasco Pro (Tempus Labs Inc), Kathleen Burke (AstraZeneca), Roy Rabbie (AstraZeneca), Ana Stewart (AstraZeneca), Mark Cobbold (AstraZeneca), Ross Stewart, PhD (AstraZeneca), Benjamin Sidders (Tempus Labs Inc), Sajan Khosla (AstraZeneca), Scott Hammond (AstraZeneca), Douglas Palmer (AstraZeneca), Martin L Miller, PhD (AstraZeneca)

This study assessed acquired and primary resistance in a real-world setting, comparing clinical features and immunogenomic drivers of resistance to ICB across major cancers, mainly NSCLC, TNBC, HNC, and bladder cancer, using de-identified multi-modal patient records. Acquired and primary resistant patients have fundamentally distinct clinical and molecular features at progression, with acquired resistant patients having signatures of an inflamed tumor microenvironment infiltrated with immune cells. This extensive, multi-modal real-world dataset, which includes >1500 post-therapy biopsies, provides insight into patient selection strategies for ICB therapy and rationale for combination treatment options for acquired resistant patients.

Time
9:00am – 8:30pm PDT

Location
Exhibit Hall B
Presentation Number
636

BASECAMP-1: A master prescreening study to identify patients with high-risk or metastatic solid tumors with HLA loss of heterozygosity (LOH) in preparation for TmodTM CAR T-cell therapy trials

Authors
Diane M. Simeone (New York University Langone Health), J. Randolph Hecht (David Geffen School of Medicine at University of California), Caleb Smith (Mayo Clinic), Marwan Fakih (City of Hope), Theodore Welling (New York University Langone Health), Edward Garon (David Geffen School of Medicine at University of California), M. Pia Morelli (The University of Texas MD Anderson Cancer Center), Patrick M. Grierson (Washington University in Saint Louis), Kedar Kirtane (Moffitt Cancer Center), Peter Vu (University of California San Diego Health), Saurabh Dahiya (Stanford Medicine), Frederick Locke (Moffitt Cancer Center), Oliver Dorigo (Stanford Medicine), Jong Chul Park (Massachusetts General Hospital), Caron Jacobson (Dana-Farber Cancer Institute), Jennifer Specht (Fred Hutchinson Cancer Center), Tomislav Dragovich (Banner MD Anderson Cancer Center), Ariane Lozac’hmeur (Tempus Labs, Inc.), Jessica Tebbets (A2 Biotherapeutics, Inc.), Gayanie Ong (A2 Biotherapeutics, Inc.), William Y. Go (A2 Biotherapeutics, Inc.), John Welch (A2 Biotherapeutics, Inc.), Eric W. Ng (A2 Biotherapeutics, Inc.), David Maloney (Fred Hutchinson Cancer Center), Marcela Maus (Massachusetts General Hospital), Julian R. Molina (Mayo Clinic)

BASECAMP-1 is an ongoing prescreening study to: 1) Identify patients with tumor-associated HLA LOH and eligibility for Tmod CAR T-cell therapy, and 2) Obtain leukapheresis in preparation for the autologous CAR T-cell therapy trials EVEREST-1 (A2B530 targeting carcinoembryonic antigen; NCT05736731) and EVEREST-2 (A2B694 targeting mesothelin). This study demonstrated the feasibility of leveraging a diagnostic during routine clinical workup to identify rare, molecularly defined patients for personalized clinical studies.

Time
9:00am – 8:30pm PDT

Location
Exhibit Hall B
Presentation Number
634

EVEREST-1: A seamless phase 1/2 study of CEA logic-gated Tmod CAR T-cell therapy (A2B530) in patients with solid tumors associated with CEA expression also exhibiting HLA loss of heterozygosity (LOH)

Authors
Salman Punekar (New York University Langone Health), Theodore Welling (New York University Langone Health), J. Randolph Hecht (David Geffen School of Medicine at University of California at Los Angeles), Julian R. Molina (Mayo Clinic), Caleb Smith (Mayo Clinic), Edward Garon (David Geffen School of Medicine at University of California at Los Angeles), M. Pia Morelli (The University of Texas MD Anderson Cancer Center), Marwan Fakih (City of Hope), Kedar Kirtane (Moffitt Cancer Center), Patrick Grierson (Washington University in Saint Louis), Sandip P. Patel (University of California, San Diego), Yi Lin (Mayo Clinic), Scott Kopetz (The University of Texas MD Anderson Cancer Center), Frederick L. Locke (Moffitt Cancer Center), Jeffrey Ward (Washington University in Saint Louis), Ariane Lozac’hmeur (Tempus Labs, Inc.), Matthew Frigault (Massachusetts General Hospital), Sarah Nikiforow (Dana-Farber Cancer Institute), Wen-Kai Weng (Stanford University), Jennifer Specht (Fred Hutchinson Cancer Center), Tomislav Dragovich (Banner MD Anderson Cancer Center), Judy Vong (A2 Biotherapeutics, Inc.), Armen Mardiros (A2 Biotherapeutics, Inc.), Kirstin Liechty (A2 Biotherapeutics, Inc.), William Y. Go (A2 Biotherapeutics, Inc.), John Welch (A2 Biotherapeutics, Inc.), Eric W. Ng (A2 Biotherapeutics, Inc.), Marcela Maus (Massachusetts General Hospital), David Maloney (Fred Hutchinson Cancer Center), Diane M. Simeone (New York University Langone Health)

EVEREST-1 (NCT05736731) is a seamless, phase 1/2, open-label, nonrandomized study to evaluate the safety and efficacy of A2B530, a logic-gated CEA-targeting Tmod CAR T-cell therapy, in adult patients. Specificity for tumor cells is provided by a blocker that recognizes human leukocyte antigen (HLA) A*02, which is absent on tumor cells with HLA-A*02 LOH [6]. LOH for HLA-A*02 is observed in solid tumor malignancies. With this definitive discriminator target, A2B530 can potentially provide a therapeutic window to treat patients with CEA-expressing solid tumors exhibiting HLA LOH.

Time
9:00am – 8:30pm PDT

Location
Exhibit Hall B
Presentation Number
376

Overcoming tumor heterogeneity – Clinical trial assays to prospectively assign patients customized multiplexed TCR-T cell therapy in Phase 1

Authors
Ribhu Nayar, Shazad A Khokhar, Jeffery Coleman, Adam Hsuing, Chunghun Chang, Henry Tsai, Shehla Arain, Ariane Lozachmeur, Andrew Nguyen, Jessica Rathbun, Qidi Yang, Ruey Pham, Sam Harris, Shardul Soni, Tyler Danek, Katie Marshall, Amanda Jensen, Chris Riley, Sveta Padmanabhan, Nancy Nabilsi, Teagan Parsons, Livio Dukaj, Alexander Cristofaro, Yun Wang, Erica Buonomo, Cagan Gurer, Antoine J Boudot, Shrikanta Chattopadhyay, Debora Barton, Gavin MacBeath

In this study, TScan characterized >190 tumor samples to understand target and HLA heterogeneity with the goal of enabling prospective patient selection for treatment with T-plex. T-Plex is a multiplexed TCR-T cell therapy product consisting of customized combinations of TCR-T cell products selected based on patient-specific intact HLAs and targets with the goal of driving complete responses. Overall, TScan’s data highlights the limitation of current TCR-T cell therapies and the unmet need to screen, select and treat patients with customized combinations of TCR-T cell products to overcome the challenge of target and HLA heterogeneity and immune escape.

Schedule a meeting with us

We'll be in touch shortly.